Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled ...
Piper Sandler analyst David Amsellem reiterates Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price...
Toast, Teva, Vistra, Equinix, Applovin, IFF, Constellation, Emerson, IP, and STERIS were top performers last week. Are they in ...
Barclays analyst Balaji Prasad maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target...
Results from the Phase 3 SOLARIS trial of TEV-‘749 for schizophrenia treatment. SteadyTeq technology ensures controlled olanzap...
U.S. stocks are on track for a mixed start on Wednesday as the market digests mixed earnings reports and looks ahead to more sp...
